Company intelligence / Profile preview

Duo Oncology

Pittsburgh, Pennsylvania, United Statesduooncology.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Duo Oncology is developing ultrasmall nanomedicines that can penetrate difficult-to-target tumors surrounded by dense stromal tissue. Their lead product, DUO-207, has shown superior efficacy and safety compared to standard therapies in GLP toxicology studies and is preparing for Phase 1 clinical trials. In toxicology studies, DUO-207's combination of gemcitabine and paclitaxel reduced symptoms of nausea and weight loss compared to the standard of care in both rats and dogs.

Therapeutic areas: OncologyHematology
Modalities: NanomedicinesSmall molecule drugs
Industry: Biotech

Drug pipeline

2 assets

DUO-209

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

University of Pittsburgh

Beyond the preview

Go deeper on Duo Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Duo Oncology.

Explore the full profile